Earnings Disappointment: Recent chatter on X about Novo Nordisk (NVO) centers on the company’s underwhelming Q3 earnings and repeated downward revisions to its 2025 guidance. Many users express concern over the slashed operating profit growth forecasts, seeing it as a sign of weakening momentum. The stock has taken a hit, with shares down significantly year-to-date.
Competitive Pressure: Discussions also highlight growing competition, especially as rival Eli Lilly reaches a $1 trillion market cap. Some on X note Novo Nordisk’s struggle to maintain dominance in the obesity and diabetes treatment markets amid pricing pressures. A few remain optimistic, pointing to potential catalysts like oral Wegovy and upcoming data readouts.
Analyst Sentiment: Posts on X reflect a mixed bag of analyst opinions, with some downgrades citing patent expiry risks for key drugs like Semaglutide by 2031. Others see long-term upside, with price targets suggesting significant growth if the company navigates current challenges. The debate keeps investors engaged as the stock hovers near multi-year lows.
Note: This discussion summary was generated from an AI condensation of post data.
Novo Nordisk Congressional Stock Trading
Members of Congress have traded $NVO stock 11 times in the past 6 months. Of those trades, 9 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $NVO stock by members of Congress over the last 6 months:
- REPRESENTATIVE MARJORIE TAYLOR GREENE has traded it 3 times. They made 3 purchases worth up to $80,000 on 10/15, 08/28, 08/19 and 0 sales.
- REPRESENTATIVE LISA C. MCCLAIN has traded it 4 times. They made 2 purchases worth up to $30,000 on 09/11, 06/09 and 2 sales worth up to $30,000 on 08/04, 07/10.
- REPRESENTATIVE SCOTT FRANKLIN has traded it 4 times. They made 4 purchases worth up to $95,000 on 08/04 and 0 sales.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
Novo Nordisk Hedge Fund Activity
We have seen 652 institutional investors add shares of Novo Nordisk stock to their portfolio, and 908 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JENNISON ASSOCIATES LLC removed 17,659,339 shares (-93.5%) from their portfolio in Q3 2025, for an estimated $979,916,721
- FRANKLIN RESOURCES INC added 13,658,867 shares (+4190.8%) to their portfolio in Q3 2025, for an estimated $757,930,529
- KINGSTONE CAPITAL PARTNERS TEXAS, LLC removed 10,005,216 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $555,189,435
- CLEARBRIDGE INVESTMENTS, LLC removed 7,332,020 shares (-89.2%) from their portfolio in Q3 2025, for an estimated $406,853,789
- SUSTAINABLE GROWTH ADVISERS, LP removed 6,187,063 shares (-99.9%) from their portfolio in Q3 2025, for an estimated $343,320,125
- CAPITAL INTERNATIONAL INVESTORS added 6,092,192 shares (+52.4%) to their portfolio in Q3 2025, for an estimated $338,055,734
- BOSTON PARTNERS added 5,571,017 shares (+inf%) to their portfolio in Q3 2025, for an estimated $309,135,733
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Novo Nordisk Analyst Ratings
Wall Street analysts have issued reports on $NVO in the last several months. We have seen 3 firms issue buy ratings on the stock, and 2 firms issue sell ratings.
Here are some recent analyst ratings:
- Jefferies issued a "Underperform" rating on 10/27/2025
- HSBC issued a "Buy" rating on 10/02/2025
- Morgan Stanley issued a "Underweight" rating on 09/29/2025
- Berenberg issued a "Buy" rating on 09/17/2025
- TD Cowen issued a "Buy" rating on 08/19/2025
To track analyst ratings and price targets for Novo Nordisk, check out Quiver Quantitative's $NVO forecast page.
Novo Nordisk Price Targets
Multiple analysts have issued price targets for $NVO recently. We have seen 4 analysts offer price targets for $NVO in the last 6 months, with a median target of $62.5.
Here are some recent targets:
- Evan David Seigerman from BMO Capital set a target price of $55.0 on 10/14/2025
- Rajesh Kumar from HSBC set a target price of $70.0 on 10/02/2025
- Thibault Boutherin from Morgan Stanley set a target price of $47.0 on 09/29/2025
- Michael Nedelcovych from TD Cowen set a target price of $70.0 on 08/19/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
